The US FDA has accepted the new drug application (NDA) for BeOne Medicines’ B-cell lymphoma 2 (BCL2) inhibitor, sonrotoclax.
This licensing deal falls under SK's wider ploy to harness the growing promise of radiopharmaceuticals within the oncology ...
With a population of over 670 million people in ASEAN, the total number of patients experiencing rare diseases and conditions ...
Corstasis Therapeutics is to collaborate with CVL on the adoption and integration of the Enbumyst nasal spray into heart ...
The use of real-world evidence (RWE) began gaining traction decades ago, primarily as a response to the limitation around ...
During the UK’s Autumn Budget, Rachel Reeves has unveiled further technology investments for the UK’s National Health Service ...
The approval marks the first for a targeted treatment in chronic spontaneous urticaria in Europe in over a decad ...
TriLink BioTechnologies senior scientist Dr Cody Palumbo discusses the blockers to manufacturing mRNA-based gene editing ...
The path from discovery to lifechanging therapy shouldn't be blocked by manufacturing limitations. MasterControl offers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback